Table II.
Immunohistochemical analysis: The expression of HLA-A, Fas, CCR5, FasL and HLA-E among the four groups.
| No. of patients | ||||||
|---|---|---|---|---|---|---|
| Protein expression | Normal mucosa (n=15) | Adenoma (n=15) | Early cancer (n=15) | Advanced cancer (n=15) | P-value | P'-value |
| HLA-A | 0.460 | 0.682 | ||||
| Negative | 0 | 0 | 2 | 1 | ||
| Weak | 2 | 4 | 3 | 1 | ||
| Strong | 13 | 11 | 10 | 13 | ||
| Fas | 0.0271 | 0.0239 | ||||
| Negative | 3 | 1 | 8 | 8 | ||
| Weak | 4 | 7 | 3 | 5 | ||
| Strong | 8 | 7 | 4 | 2 | ||
| CCR5 | <0.001 | 0.176 | ||||
| Negative | 14 | 7 | 2 | 2 | ||
| Weak | 1 | 3 | 5 | 5 | ||
| Strong | 0 | 5 | 8 | 8 | ||
| FasL | <0.001 | 0.605 | ||||
| Negative | 15 | 10 | 8 | 4 | ||
| Weak | 0 | 5 | 5 | 8 | ||
| Strong | 0 | 0 | 2 | 3 | ||
| HLA-E | <0.001 | <0.001 | ||||
| Negative | 15 | 15 | 5 | 3 | ||
| Weak | 0 | 0 | 9 | 6 | ||
| Strong | 0 | 0 | 1 | 6 | ||
The P-value is comparison amongst 4 groups, P' adenoma group vs. early cancer group. HLA-A, human leukocyte antigen-A; Fas, apoptosis antigen 1; CCR5, C-C chemokine receptor type 5; FasL, apoptosis antigen 1 ligand; HLA-E, human leukocyte antigen class I histocompatibility antigen, alpha chain E.